Latest Breaking News On - Jim denike - Page 1 : comparemela.com

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Molly cameronJim denikeMarinus pharmaceuticalsCompany contactsExchange commissionCorporate communications investor relationsMarinus pharmaceuticals incCompensation committeeNasdaq listing ruleCommon stockPrivate securities litigation reform actInvestor relationsCorporate communications

Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc and Provides Update on Marinus Post Grant Review

Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc and Provides Update on Marinus Post Grant Review
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jim denikeMolly cameronScott braunsteinMarinus pharmaceuticals incExchange commissionPatent officeOvid therapeutics incCorporate communications investor relationsMarinus pharmaceuticalsInter partes reviewOvid therapeuticsMarinu phasePatent trialAppeal boardPrivate securities litigation reform actInvestor relations

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

RADNOR, Pa. (BUSINESS WIRE) Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to four new employees. The Compensation Committee of the Board of Directors of Marinu.

Molly cameronJim denikeMarinus pharmaceuticals incMarinus pharmaceuticalsCompany contactsCorporate communications investor relationsExchange commissionCompensation committeeNasdaq listing ruleCommon stockPrivate securities litigation reform actInvestor relationsCorporate communications

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Jim denikeMolly cameronExchange commissionMarinus pharmaceuticals incCorporate communications investor relationsMarinus pharmaceuticalsCompensation committeeNasdaq listing ruleCommon stockPrivate securities litigation reform actInvestor relationsCorporate communications

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

RADNOR, Pa. (BUSINESS WIRE) Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to four new employees. The Compensation Committee of the Board of Directors of Marinu.

Molly cameronJim denikeMarinus pharmaceuticals incCorporate communications investor relationsExchange commissionMarinus pharmaceuticalsCompany contactsCompensation committeeNasdaq listing ruleCommon stockPrivate securities litigation reform actInvestor relationsCorporate communications